Bioavailability Enhancement Technologies
A study conducted on terminated drug development projects revealed that majority of the drug candidates fail in early drug development phases, due to the problems associated with their pharmacokinetic profiles, ADME properties and toxicity-related issues. Moreover, it is a well-established fact that the systemic / local absorption and distribution of a therapeutic intervention is directly proportional to its bioavailability. In this context, it is also worth highlighting that more than 90% of new chemical entities (NCEs) developed by pharmaceutical companies and nearly 40% of the top-ranking oral drugs marketed in North America and Europe are insoluble in water and, hence, their low solubility can lead to deficient drug concentration, which further leads to in vivo failure. As a result, a large number of companies are now considering adopting various types of bioavailability enhancement technologies in order to ensure that their proprietary pharmacological product candidates are made bioavailable at optimal quantities at the desired site of action.
For additional details, please visit